Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06929702 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children

Study acronym: MOMENTUM
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Start date changed from estimate of Apr 22, 2025 to Jul 9, 2025
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.
Trial Details
NCT Number NCT06929702
Lead Sponsor University Hospital, Ghent
Conditions
(from sponsor)		 Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov